304 related articles for article (PubMed ID: 21676289)
1. Oncolytic virotherapy for pancreatic cancer.
Wennier S; Li S; McFadden G
Expert Rev Mol Med; 2011 May; 13():e18. PubMed ID: 21676289
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer.
Zhang Y; Li Y; Chen K; Qian L; Wang P
J Cancer Res Ther; 2022 Sep; 18(5):1247-1255. PubMed ID: 36204869
[TBL] [Abstract][Full Text] [Related]
3. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.
Cuddington BP; Mossman KL
J Virol; 2014 Jun; 88(12):6885-95. PubMed ID: 24696490
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
[TBL] [Abstract][Full Text] [Related]
5. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
Carew JS; Espitia CM; Zhao W; Kelly KR; Coffey M; Freeman JW; Nawrocki ST
Cell Death Dis; 2013 Jul; 4(7):e728. PubMed ID: 23868061
[TBL] [Abstract][Full Text] [Related]
6. The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer.
Sato-Dahlman M; Yamamoto M
Curr Cancer Drug Targets; 2018; 18(2):153-161. PubMed ID: 28228084
[TBL] [Abstract][Full Text] [Related]
7. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?
Tassone E; Muscolini M; van Montfoort N; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():141-148. PubMed ID: 32859494
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?
Yoon AR; Hong J; Jung BK; Ahn HM; Zhang S; Yun CO
Cancer Lett; 2023 Nov; 579():216456. PubMed ID: 37940067
[TBL] [Abstract][Full Text] [Related]
10. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
11. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.
Chu QD; Sun G; Pope M; Luraguiz N; Curiel DT; Kim R; Li BD; Mathis JM
Surgery; 2012 Sep; 152(3):441-8. PubMed ID: 22853858
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
Sadri M; Najafi A; Rahimi A; Behranvand N; Hossein Kazemi M; Khorramdelazad H; Falak R
Int Immunopharmacol; 2023 Sep; 122():110470. PubMed ID: 37433246
[TBL] [Abstract][Full Text] [Related]
13. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
14. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.
Nistal-Villan E; Bunuales M; Poutou J; Gonzalez-Aparicio M; Bravo-Perez C; Quetglas JI; Carte B; Gonzalez-Aseguinolaza G; Prieto J; Larrea E; Hernandez-Alcoceba R
Mol Cancer; 2015 Dec; 14():210. PubMed ID: 26671477
[TBL] [Abstract][Full Text] [Related]
15. Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene.
Xu B; Zheng WY; Jin DY; Wang DS; Liu XY; Qin XY
Cancer; 2012 Nov; 118(21):5217-26. PubMed ID: 22517373
[TBL] [Abstract][Full Text] [Related]
16. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
[TBL] [Abstract][Full Text] [Related]
17. Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
Ellerhoff TP; Berchtold S; Venturelli S; Burkard M; Smirnow I; Wulff T; Lauer UM
Int J Oncol; 2016 Nov; 49(5):1931-1944. PubMed ID: 27601235
[TBL] [Abstract][Full Text] [Related]
18. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy.
Kasuya H; Nishiyama Y; Nomoto S; Goshima F; Takeda S; Watanabe I; Nomura N; Shikano T; Fujii T; Kanazumi N; Nakao A
Cancer Gene Ther; 2007 Jun; 14(6):533-42. PubMed ID: 17415379
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy for cancer treatment: challenges and solutions.
Davis JJ; Fang B
J Gene Med; 2005 Nov; 7(11):1380-9. PubMed ID: 16025557
[TBL] [Abstract][Full Text] [Related]
20. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer.
Kangasniemi L; Parviainen S; Pisto T; Koskinen M; Jokinen M; Kiviluoto T; Cerullo V; Jalonen H; Koski A; Kangasniemi A; Kanerva A; Pesonen S; Hemminki A
Int J Cancer; 2012 Jul; 131(1):253-63. PubMed ID: 21834073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
